RCMNY
FLNA

Rubric Capital Management (New York)’s Filana Therapeutics FLNA Stock Holding History

Rubric Capital Management (New York)’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-69,401
Closed -$2.58M – 95
2022
Q1 		$2.58M Buy
+69,401
New +$2.94M 0.09% 67

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Rubric Capital Management (New York)'s FLNA Position: Q2 2022 in Review

Rubric Capital Management (New York) sold out of Filana Therapeutics (FLNA) in Q2 2022, closing a stake of 69,401 shares — an estimated $2.58M sold.

Rubric Capital Management (New York) first reported a position in FLNA in Q1 2022 and held it in 1 quarter. The position peaked at $2.58M in Q1 2022. 149 funds tracked by Wall St. Rank hold FLNA as of Q2 2022.

  • Rubric Capital Management (New York) reported no remaining Filana Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 69,401 Filana Therapeutics shares in Q2 2022, an estimated $2.58M.
  • Rubric Capital Management (New York) first reported a position in Filana Therapeutics in Q1 2022 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Filana Therapeutics position peaked at $2.58M in Q1 2022.
  • 149 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2022, filed 12 Aug 2022.